<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154400</url>
  </required_header>
  <id_info>
    <org_study_id>109237</org_study_id>
    <nct_id>NCT01154400</nct_id>
  </id_info>
  <brief_title>Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients</brief_title>
  <official_title>Grant Title: Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas A&amp;M University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the first aim of a NIH project that consists of 3 aims. The first&#xD;
      aim examines the acute effects of two high-quality milk proteins (casein vs. whey) on&#xD;
      whole-body and muscle protein metabolism in COPD patients with severe loss of muscle mass and&#xD;
      the effects of adding leucine. The principal endpoints will be the extent of stimulation of&#xD;
      net whole body protein synthesis as this is the principal mechanism by which either amino&#xD;
      acid or protein intake causes muscle anabolism. After determining the optimal nutritional&#xD;
      formulation based on the first aim we will continue to work on the second and third aim where&#xD;
      fish oil supplementation will be part of the nutritional intervention as well.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cachectic COPD patients are characterized by a decreased muscle protein synthesis and an&#xD;
      elevated myofibrillar protein breakdown. A substantial number of these patients,&#xD;
      characterized by an enhanced systemic inflammatory response, fails to respond to nutritional&#xD;
      therapy, which is of clinical relevance as weight gain to nutritional therapy is a&#xD;
      significant, independent predictor of mortality in COPD.&#xD;
&#xD;
      In the present study, the acute protein anabolic effect of two high-quality milk protein&#xD;
      supplements in COPD will be examined by comparing a hydrolyzed casein and whey protein meal.&#xD;
      We make use of hydrolyzed proteins to correct for absorption differences. Furthermore the&#xD;
      effects of these milk proteins with or without enrichment of leucine will be investigated.&#xD;
&#xD;
      Variables of interest are: net whole body protein synthesis; whole body protein synthesis and&#xD;
      breakdown rate; whole body myofibrillar protein breakdown rate; whole body collagen&#xD;
      breakdown; kinetics of insulin; glucose; amino acid levels.&#xD;
&#xD;
      It is the investigators hypothesis that a nutritional supplement containing casein protein&#xD;
      and high levels of leucine will target the metabolic alterations of these cachectic COPD&#xD;
      patients and will specifically stimulate protein anabolism. The knowledge gained from this&#xD;
      study will benefit our insight in terms of promotion of protein anabolism in COPD patients.&#xD;
      The long-term goal is to reformulate nutritional composition in accord with the effects of&#xD;
      COPD on protein metabolism in order to ameliorate or even prevent progressive muscle wasting&#xD;
      in these subjects, and improve their quality of life and survival rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in net whole body protein balance</measure>
    <time_frame>6 hours</time_frame>
    <description>Net whole body protein synthesis before and after protein feeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in whole body protein synthesis rate</measure>
    <time_frame>6 hours</time_frame>
    <description>Whole body protein synthesis before and after protein feeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole body protein breakdown rate</measure>
    <time_frame>6 hours</time_frame>
    <description>Whole body protein breakdown rate before and after protein feeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole body collagen breakdown</measure>
    <time_frame>6 hours</time_frame>
    <description>Whole body collagen breakdown before and after protein feeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin concentration</measure>
    <time_frame>6 hours</time_frame>
    <description>Plasma insulin during protein feeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose concentration</measure>
    <time_frame>6 hours</time_frame>
    <description>Plasma glucose concentration during protein feeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma amino acid levels</measure>
    <time_frame>6 hours</time_frame>
    <description>Plasma amino acid level during protein feeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole body myofibrillar protein breakdown rate</measure>
    <time_frame>6 hours</time_frame>
    <description>Whole body myofibrillar protein breakdown before and after protein feeding</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Casein protein hydrolysates</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 g casein protein hydrolysates and 15 g maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whey protein hydrolysates</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 g whey protein hydrolysates and 15 g maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Casein protein hydrolysates + LEU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 g casein protein hydrolysates + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whey protein hydrolysates + LEU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 g whey protein hydrolysates + 1.5 g LEU (40% of EAA content) + 15 g maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Casein protein hydrolysates</intervention_name>
    <description>15 g casein protein hydrolysates + 15 g maltodextrin</description>
    <arm_group_label>Casein protein hydrolysates</arm_group_label>
    <other_name>Casein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey protein hydrolysates</intervention_name>
    <description>15 g whey protein isolate + 15 g maltodextrin</description>
    <arm_group_label>Whey protein hydrolysates</arm_group_label>
    <other_name>Whey</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Casein protein hydrolysates + LEU</intervention_name>
    <description>15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin</description>
    <arm_group_label>Casein protein hydrolysates + LEU</arm_group_label>
    <other_name>Casein + LEU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey protein hydrolysates + LEU</intervention_name>
    <description>15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion</description>
    <arm_group_label>Whey protein hydrolysates + LEU</arm_group_label>
    <other_name>Whey + LEU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of moderate to severe chronic airflow limitation, defined as measured forced&#xD;
             expiratory volume in one second (FEV1) ≤ 70% of reference FEV1&#xD;
&#xD;
          -  Shortness of breath on exertion&#xD;
&#xD;
          -  Age 45 years and older&#xD;
&#xD;
          -  Clinically stable condition and not suffering from respiratory tract infection or&#xD;
             exacerbation of their disease (defined as a combination of increased cough, sputum&#xD;
             purulence, shortness of breath, systemic symptoms such as fever) at least 4 weeks&#xD;
             prior to the study&#xD;
&#xD;
          -  Cachexia based on the criteria: Body mass index ≤ 25 kg/m2 and/or FFM-Index:&#xD;
             FFM/height2 ≤ 17 (males), 15 (females) kg/m2 and/or recent involuntary weight loss&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Established diagnosis of malignancy&#xD;
&#xD;
          -  Presence of fever within the last 3 days&#xD;
&#xD;
          -  Established diagnosis of Diabetes Mellitus&#xD;
&#xD;
          -  Untreated metabolic diseases including hepatic or renal disorder&#xD;
&#xD;
          -  Presence of acute illness or metabolically unstable chronic illness&#xD;
&#xD;
          -  Recent myocardial infarction (less than 1 year)&#xD;
&#xD;
          -  Use of long-term oral corticosteroids or short course of oral corticosteroids in the&#xD;
             preceding month before enrollment&#xD;
&#xD;
          -  Allergy to cow's milk protein&#xD;
&#xD;
          -  Any other condition according to the PI or study physicians would interfere with&#xD;
             proper conduct of the study / safety of the patient&#xD;
&#xD;
          -  Failure to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marielle Engelen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas A&amp;M University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <last_update_submitted>October 11, 2012</last_update_submitted>
  <last_update_submitted_qc>October 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas A&amp;M University</investigator_affiliation>
    <investigator_full_name>Marielle PKJ Engelen, PhD</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>casein protein</keyword>
  <keyword>whey protein</keyword>
  <keyword>hydrolysates</keyword>
  <keyword>leucine</keyword>
  <keyword>protein metabolism</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caseins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

